Midi Health
Insurance-covered virtual clinic treating menopause and midlife hormonal symptoms.
On the record
Checkpoint: Outcome of N.C. et al v. Midi Health federal lawsuit (discovery/settlement)
The call
Midi has real patients, real payer contracts, and real legal and profitability questions running side by side.
Midi Health is an online doctor service focused on menopause treatment that works with insurance companies to get paid, not just patients paying out of pocket. It is hard to copy because doctors need special licenses in each state to prescribe menopause hormones, insurance companies take years to set up payment relationships, and hospitals and clinics have already signed deals with Midi. The biggest risk is whether Midi can make real profit, whether it faces legal trouble for how it advertises, or whether larger telehealth companies like Ro or Nurx decide to start offering menopause care through insurance too.
Why
01
AI pressure: None apparent. Prescribing hormone therapy requires licensed clinicians, so AI symptom bots and chat tools can't replace the actual care loop. Could AI do the core job? Unlikely.
02
Bigger players: Hims & Hers, Ro. Both have cash, brand reach, and telehealth infrastructure to build insurance-based menopause lines and target Midi's patient base. Could a giant copy it? Probably.
03
What protects it. Years-long insurance credentialing, multi-state licensure, and payer contracts covering about 45M women are hard to copy fast.
What would change this call
Outcome of N.C. et al v. Midi Health lawsuit filed March 2025. Would show legal exposure and potential financial or operational impact.
Number of states approving Midi's testosterone therapy beyond the initial 12. Would show regulatory expansion pace and market reach growth.
Public disclosure of Midi's profitability or audited revenue figures. Would clarify actual financial health versus the $40M-$150M range reported.
Number of states approving Midi's testosterone therapy beyond the initial 12. Would show regulatory expansion pace and market reach growth.
Public disclosure of Midi's profitability or audited revenue figures. Would clarify actual financial health versus the $40M-$150M range reported.
Key numbers
- $150M annualized revenue run-rate
- About 25,000 weekly patients
- Payer contracts cover about 45M women
Named risks
- Not yet profitable despite raising over $250M and reaching over $1B valuation by February 2026.
- Active federal lawsuit N.C. et al v. Midi Health filed March 26 2025, outcome unresolved.
- NAD forced discontinuation of a patient outcome ad claim in February 2026, signaling regulatory scrutiny.
- Revenue and patient count figures conflict across sources and rely heavily on company self reported claims.
- Well funded incumbents Hims & Hers, Ro, and Maven Clinic could enter insurance based menopause care and erode differentiation.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Alloy Health | contesting | Direct cash-pay menopause telehealth rival, compared head to head in 2026 buyer guides |
| Evernow | contesting | Competing menopause telehealth platform frequently listed alongside Midi in 2026 comparisons |
| Winona | contesting | Rival in compounded bioidentical HRT, compared on pricing as of May 2026 |
| Hims & Hers | gaining on | Larger DTC telehealth incumbent that could enter insurance based menopause care, not yet done as of 2026 |
| Ro | gaining on | Entered women's health via Serena Williams partnership, seen as potential menopause entrant in 2026 |
| Maven Clinic | gaining on | Flagged as unbarred menopause care competitor with lower structural friction to pivot in, as of July 2026 |
Questions people ask
- Is Midi Health profitable in 2026?
- No. As of October 2025 third party analysis, Midi Health was not yet profitable. It closed a $100M Series D on February 3, 2026 at a valuation over $1B, signaling it is still prioritizing growth over near-term profit.
- Who owns Midi Health?
- Midi Health is privately held, founded in 2021 by Joanna Strober and Sharon Meers. It has no parent company. Investors as of its February 3, 2026 Series D include Goodwater Capital, Foresite Capital, Serena Ventures, GV, and Felicis Ventures.
- Could AI replace Midi Health's doctors?
- No. Prescribing HRT and testosterone therapy legally requires licensed clinicians and state medical licensure. Midi uses AI for scribing via its Ambience Healthcare partnership, started January 2024, and admin work, not for diagnosis or prescribing itself.
- Who is Midi Health's biggest competitor?
- Cash-pay menopause telehealth rivals Alloy Health, Evernow, and Winona compete directly. Larger incumbents Hims & Hers and Ro, plus Maven Clinic, are seen as potential entrants into Midi's insurance-billed menopause niche as of 2026.
- How much funding has Midi Health raised?
- Midi Health has raised over $250M total: a $14M seed in October 2022, $25M Series A in September 2023, roughly $60M Series B in 2024, $50M Series C in October 2025, and $100M Series D on February 3, 2026 at over $1B valuation.
- Does Midi Health take insurance for menopause care?
- Yes. Insurance-covered care is Midi's core model, differentiating it from many cash-pay rivals. The company stated on February 3, 2026 that its payer contracts cover more than 45 million women, with over 25,000 patients using the platform weekly.
Timeline
- 2026-06-23Launched prescription strength hormonal skincare line including Estriol+ Face Cream
- 2026-02-25NAD forced Midi to discontinue '91% relief in 2 months' Instagram ad claim
- 2026-02-03Closed $100M Series D led by Goodwater Capital, valuation surpasses $1B
- 2025-10-30Launched testosterone therapy for women across 12 states
- 2025-10-02Raised $50M Series C to scale care and build AI search for women's health
- 2025-03-26N.C. et al v. Midi Health Inc lawsuit filed in N.D. California
- 2024-01-15Partnered with Ambience Healthcare for generative AI clinical documentation
- 2023-09Raised $25M Series A led by GV (Google Ventures)
- 2022-10Raised $14M seed round led by SemperVirens
- 2021-01Founded by Joanna Strober and Sharon Meers
Revision history
22 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources